This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This poses a significant challenge for pharmaceuticalmanufacturers, not least because of the technical challenges related to operations, supply chain and the environment. This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products.
Revolutionising quality control In the backdrop of stringent quality standards and regulatory demands inherent to pharmaceuticalmanufacturing, the addition of AI technologies introduce a paradigm shift. Tuijin Jishu/Journal of Propulsion Technology, 44(3), 1384-1392.
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceuticalmanufacturing in the EEA, is implemented.
To address these issues, companies should adopt more advanced production strategies such as continuous flow chemistry, as they can shorten manufacturing processes, increase productivity and throughput. Simultaneously, there is increasing need for stringent quality control and traceability throughout the supply chain to ensure patient safety.
The first industrial-scale pharmaceuticalmanufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. During the earlier announcement for its French facility, Orano Med highlighted one key challenge of developing lead-212 based radioligand therapies is manufacturing then on an industrial scale.
Novo Nordisk has announced plans to invest over 42 billion Danish kroner (nearly £5 billion) starting in 2023, to expand its manufacturing facilities in Kalundborg, Denmark. According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging.
Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceuticalmanufacturing campus in Middletown, Delaware, US. WuXi STA has 12 sites across the US, Europe and Asia. This campus is only possible because of Delaware’s world-class, innovative workforce.
In the past 12 months, PhRMA and closely allied groups spent at least $57 million — $19 million of it since July — on TV , cable , radio , and social media ads opposing price negotiations, according to monitoring by the advocacy group Patients for Affordable Drugs. First, let’s clarify how the bill saves taxpayers billions.
The involvement of patient voice in demonstrating the value of treatments in healthcare is gaining importance. While gaining patient insights is not a new topic for biopharmaceutical teams, the body of literature on the role of patient-centricity in health technology assessments (HTA) is growing. ACCESS THE FULL ARTICLE HERE.
When we think of adherence in the medical world, it’s often simplified to something along the lines of the degree to which a patient correctly follows medical advice. It’s a simple statement with many, many moving parts, especially when we’re talking about patients with multiple chronic conditions. So how is this achieved?
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Say goodbye to all the supposed goodwill.
Eli Lilly and Company (Lilly) has unveiled plans to invest $1.6bn in its two new manufacturing facilities located within the LEAP Innovation Park in Boone County, Indiana, US. The investment at the LEAP site marks the company’s biggest manufacturing investment at a single location to date.
And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. We try to have a very long-term orientation because we believe that aligns our objectives very well with the objectives of society and the patients we serve, and it makes us a stable business.”.
To appreciate the scope of the challenge facing the pharmaceutical market, as well as patients across the globe, we must understand that there are two distinct threats – ‘counterfeit’ and ‘falsified’ medicines. These may be mislabelled or produced in fake packaging and, most dangerously, there is no regulation around their manufacture.
International Federation of PharmaceuticalManufacturers and Associations (IFPMA), the global trade body for the biopharmaceutical industry , has announced its new CEO leadership team for the next two years. The site holds the world’s largest manufacturing capacity at a single site.
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceuticalmanufacturing site quality rating system, the Quality management maturity (QMM) programme.
Failing to adhere to prescribed medication regimens is one of the prime reasons for poor patient health outcomes. Pharmaceutical and healthcare companies are working continuously to improve patient adherence, which also impacts disease control and pharmaceutical industry revenues directly. Patient adherence.
For example, due to prevalence of the disease across the globe, US approval of the biologic lecanemab was particularly anticipated by both the industry and patients. The findings were published in the NEMJ in April 2023 and demonstrated “the best solid tumour CAR-T data reported to date – and by a country mile!
Our Ludwigshafen site serves as a centre of excellence for both research and development and pharmaceuticalmanufacturing and will play a critical role in AbbVie’s future growth,” stated Azita Saleki-Gerhardt , PhD, Executive Vice President, Chief Operations Officer. The new R&D building in Germany is expected to completed in 2027.
Astellas Ireland, a wholly owned subsidiary of Astellas, has officially marked the start of construction of a new €330 million manufacturing facility at Kerry Technology Park in Tralee, Ireland. Together we hope to build something best in class, producing quality products that people need, and striving to continue putting patients first.”
From the manufacturer perspective, payer policies and legislation on combination therapy pricing are impacting global development, pricing, access, and commercialization strategies. As a result, manufacturers are increasingly opting to not launch their combination indications in certain markets. Certain markets (e.g.,
The pharmaceutical industry has numerous use cases for AI. From the drug discovery phase to patient care, AI has the potential to enhance almost every stage of the product life cycle. It also has the potential to reduce the high carbon footprint associated with manufacturing.
Ensuring that these therapies reach the right patients at the right time requires a deep understanding of the patient journey and the healthcare professionals (HCPs) involved in their care. Lab data, coupled with strategic HCP engagement, plays a crucial role in helping pharmaceuticalmanufacturers navigate this complex landscape.
These advancements can enhance drug solubility and bioavailability, improve the speed to clinical trials, reduce environmental impact, and increase patient access to treatments. This uncovers opportunities to implement green chemistry principles, overhaul inefficient manufacturing techniques, and modernize outdated methods.
Zygel is the first and only pharmaceuticallymanufactured, synthetic cannabidiol that is formulated as a patient-protected permeation-enhanced gel for transdermal delivery.
It’s a powerful technology that, if used correctly, can help us all reach new heights in pharmaceuticalmanufacturing and beyond. This article will explore how to set yourself up for success when using AI within the pharma manufacturing space. It is easy and understandable to get swept into the hype around AI.
Improving our collective understanding of the patient’s overall healthcare experience is necessary to effectively deliver prescription support. How can we ensure that vital prescription information reaches patients when they need it? Where and how you message HCPs and patients must synchronize with when they are engaged.
Moreover, pharmaceuticalmanufacturing poses a huge detriment to the state of the planet’s ecosystem. Active pharmaceutical ingredients (APIs) are particularly impact intensive, soaking up a large quantity of resources in terms of heat, energy and water when being produced.
How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. But it is not a simple answer. Furthermore, it is estimated to reach $6.5
Andreas Häner (AH): Roche, along with other pharmaceutical companies, acknowledges concerns about pharmaceuticals in the environment (PiE). Wastewater samples taken at or close to the point of generation in manufacturing typically have a much higher API concentration, thus require less analytical sensitivity.
AI supports marketers in key areas such as personalized campaigns (with tailored messages to healthcare professionals (HCPs) and patients), predictive analytics, and social sentiment analysis. Respondents cite workflow automation, data analysis, and realtime content generation as areas of interest within their organizations.
Pharmacy's position at the intersection of the care team gives it a unique ability to connect providers, payers, and pharmaceuticalmanufacturers, and support patients to maximize their health outcomes.
Central Drugs Standard Control Organisation (earlier known as Drugs Controller General of India) are essential to the pharmaceutical production process. They play a crucial role in assuring the efficacy and safety of products given to patients.
The Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) Investment Programme is a joint initiative between the Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI). Importantly, NHS patients will be able to access new treatments earlier.
And as these stakeholders are presented with more and more RWE from pharmaceuticalmanufacturers, they are asking tough questions to better understand whether to use this evidence when making critical decisions that impact the health of patients.
And as these stakeholders are presented with more and more RWE from pharmaceuticalmanufacturers, they are asking tough questions to better understand whether to use this evidence when making critical decisions that impact the health of patients.
BeiGene has opened its flagship US manufacturing facility in Hopewell, New Jersey. Addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities…to advance quality medicines faster for patients,” commented John Oyler , Co-Founder, Chairman and CEO of BeiGene.
AstraZeneca has scrapped its planned 450 million expansion of a vaccine manufacturing facility in Liverpool, UK, citing economic factors and reduced government funding. AstraZeneca remains committed to its UK operations but continues to assess opportunities in regions that offer more favourable financial conditions and regulatory support.
While it officially applies to the manufacture of sterile medicinal products in the European Union, the revised EU Good Manufacturing Practice (GMP) Annex 1 effectively reset the benchmark for quality standards across the globe on 25 August 2023.
Despite physicians conducting an average of six professional searches every working day, only 17% of them searched with the words “pharmaceuticalmanufacturers.” Helpfully, Google conducted research to work out how healthcare professionals were sourcing products online.
The acquisition will expand the international solutions portfolio of AmerisourceBergen aiding in advancing its position as a preferred partner for biopharmaceutical manufacturers. This approach will support its manufacturer partners throughout the pharmaceutical development and marketing processes.
The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 3) policing anticompetitive settlements between competing drug manufacturers. 3) policing anticompetitive settlements between competing drug manufacturers. 5) monitoring access to biosimilars.
Manufacturer assistance programs are designed to make treatments more affordable, yet only about 10% of these dollars are used by patients. The cost of filling a prescription can keep 21% of patients from getting an Rx, and one in ten patients will modify their treatment plan because of cost, according to recent polling data from KFF.
Key study findings Study results demonstrated that precise control of tablet surface geometry “effectively tailored drug release profiles, enhancing patient compliance and treatment efficacy”. their approach in the study addresses “diverse pharmaceuticalmanufacturing demands”. Therefore, according to Wang et al.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content